2025 : 3 Posts

Late-Breaking Interim STENOVA Data Presented at Digestive Disease Week® 2025 Demonstrate Potential of AGMB-129 in Fibrostenosing Crohn’s Disease

Antwerp, Belgium, May 6, 2025 Agomab Therapeutics NV (“Agomab”) today announced latebreaking interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastrointestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ RI or ALK5) developed for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD). The interim results were presented by Florian Rieder,

Late-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn’s to be Presented at Digestive Disease Week® 2025

Antwerp, Belgium, April 10, 2025 – Agomab Therapeutics NV (‘Agomab’) today announced that interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ-RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD), will be presented as a late-breaking presentation at Digestive